Physician profile
Cameron Collier
NPI 1255056446
$7,967.73
in general payments reported to CMS, 2019-2025
32 companies · $3,087 in 2025
The $3,087 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.58 · 2023: $2,059 · 2024: $2,759 · 2025: $3,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,297 · Education: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,297.04 |
| Education | $608.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,311.69 | 2023-2025 | Tremfya |
| Abbvie INC. | $1,055.58 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $946.45 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $764.41 | 2023-2025 | Dupixent, Libtayo |
| Ucb, INC. | $545.90 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $453.25 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $414.17 | 2024-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $396.85 | 2022-2025 | Blu-U, Odomzo, Ilumya |
| Dermavant Sciences, INC. | $369.26 | 2023-2024 | Vtama |
| Amgen INC. | $366.38 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $247.70 | 2023-2024 | |
| Leo Pharma INC. | $216.88 | 2023-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $164.77 | 2023-2025 | Zoryve |
| Mallinckrodt Hospital Products INC. | $105.19 | 2024-2025 | Acthar |
| Pfizer INC. | $100.66 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79.74 | 2025 | |
| Kyowa Kirin, INC. | $55.44 | 2024 | Poteligeo |
| Verrica Pharmaceuticals INC. | $45.44 | 2024-2025 | Ycanth |
| Mylan Institutional INC. | $45.02 | 2023 | Hulio |
| Chiesi USA, INC. | $39.00 | 2025 | Filsuvez |
| Biofrontera INC. | $30.06 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $24.89 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $24.56 | 2023 | Evusheld |
| Organon LLC | $24.23 | 2024-2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.63 | 2023 | Spevigo |
| Alnylam Pharmaceuticals INC. | $22.35 | 2024 | Givlaari |
| Krystal Biotech INC | $18.76 | 2025 | Vyjuvek |
| Genentech USA, INC. | $17.09 | 2024 | Erivedge |
| Epi Health, LLC | $16.11 | 2022 | |
| Incyte Corporation | $15.18 | 2024 | Opzelura |
| Ani Pharmaceuticals, INC. | $13.92 | 2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.